Newsletter | September 8, 2021

09.08.21 -- New Podcast Episodes: GMP Meets RNA Cell Therapies, Cold Chain Sustainability, and more.


Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so you never miss an episode!

Voices From The Frontline Of Cell And Gene Discovery

State-Of-The-Art GMP Manufacturing RNA Cell Therapies, With Cartesian's CEO

Dr. Murat Kalayoglu, CEO at Cartesian Therapeutics, details the cell and gene therapy sector's advancements in RNA cell therapy and the why behind the company's decision to build its own wholly-owned GMP manufacturing facility.

Cell And Gene Therapy Firsts, With Dr. Bruce Levine

Dr. Bruce Levine, Barbara and Edward Netter professor in cancer gene therapy at the University of Pennsylvania, explains his road to adoptive immunotherapy trials, overcoming the gap between academia and industry, and how Philadelphia earned the Cellicon Valley name for its continued innovation in cell and gene therapy, and more.


How To Apply For Breakthrough Therapy Designation (BTD) And Win It, With Drs. Ira Gupta And Shanthi Ganeshan

Under the guidance of Ira Gupta, M.D., and Shanthi Ganeshan, Ph.D., GSK has a few breakthrough therapy designations (BTDs) under its belt. Dr. Gupta is VP of medicine development at GSK, and Dr. Ganeshan recently joined Gilead as head of regulatory for oncology. Here we discuss how to apply for — and win — BTDs with two women who couldn't be more qualified for the discussion.

Cold Chain Integrity And Sustainability, With Celyad Oncology's Thomas Lequertier

Maintaining therapeutic integrity through cryopreservation and super-cold supply chains have challenged, and continue to vex, biologics producers. On this episode, Celyad Oncology head of cell therapy manufacturing, Thomas Lequertier, shares best practices for the cryopreservation of cell therapies while minimizing cell degradation, maintaining their integrity on the journey from the lab to the patient, and what the future holds for cold chain biologics therapy logistics.

Peptides And Proteins: Resetting The Immune System, With Revolo CEO Jonathan Rigby

Revolo Biotherapeutics has entered Phase 2 with two molecules for autoimmune or allergic diseases that act to reset the immune system “upstream,” or ahead of the inflammatory cascade. Here, CEO Jonathan Rigby shares the outsourced manufacturing strategy behind the endeavor, why it is so important to avoid immune suppression, and how the therapies work to avoid it.

Intranasal Prophylactics For Flu And Coronavirus, With Leyden Labs' Koenraad Wiedhaup

We breathe in galaxies of viruses daily. As those viruses multiply and mutate, our approach to mitigating their risks is largely reactive. On this episode, Leyden Labs CEO, Koenraad Wiedhaup, explains the company’s prophylactic approach to protection from influenza and coronaviruses via a self-administered intranasal spray.